Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: Tenchusatsu who wrote (1501364)	11/13/2024 10:17:29 PM
From: i-node	1 Recommendation Recommended By longz Read Replies (1) \| Respond to of 1570499

>> Again, you really don't know WTF you're talking about. A drug that is repurposed for another use can be VERY lucrative, and there is a ton of VC money chasing after this. Exactly. That's my point. "Method of use" patents, for example, should not be allowed. Once a drug is off-patent, Or Extended Release. Or different methods of delivery, or any other cosmetic changes should not trigger additional patent benefits. Do you really think insulin that gets an improved injector should qualify for a patent or extension? >> Supplements and other "alternative" health treatments are already a huge market. Various studies have been conducted on them with very inconsistent results. Some yes, others no. The supplements market is a total circus. Shit that no one could ever benefit from, and other stuff that has been acknowledged as therapeutic for centuries or longer. I believe companies should get a fair opportunity to turn a profit, and always have. The patent system as it pertains to pharma is just ridiculous and needs to be controlled.